Research Analysts Issue Forecasts for JNJ Q1 Earnings

Johnson & Johnson (NYSE:JNJ) – Equities researchers at Leerink Partnrs issued their Q1 2025 earnings estimates for Johnson & Johnson in a research note issued to investors on Thursday, January 23rd. Leerink Partnrs analyst D. Risinger expects that the company will earn $2.55 per share for the quarter. The consensus estimate for Johnson & Johnson’s current full-year earnings is $10.56 per share. Leerink Partnrs also issued estimates for Johnson & Johnson’s Q2 2025 earnings at $2.61 EPS and Q4 2025 earnings at $2.33 EPS.

A number of other analysts also recently weighed in on the company. Wolfe Research assumed coverage on Johnson & Johnson in a research report on Friday, November 15th. They issued an “outperform” rating and a $190.00 target price for the company. Wells Fargo & Company lowered their price objective on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a report on Thursday. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Barclays decreased their price objective on Johnson & Johnson from $160.00 to $159.00 and set an “equal weight” rating on the stock in a report on Tuesday. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $181.00 target price on shares of Johnson & Johnson in a research note on Thursday. Nine research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $170.06.

Johnson & Johnson Trading Up 0.1 %

NYSE JNJ opened at $146.76 on Friday. The stock’s 50-day simple moving average is $147.99 and its two-hundred day simple moving average is $155.98. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $168.85. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The company has a market capitalization of $353.34 billion, a price-to-earnings ratio of 22.07, a PEG ratio of 2.45 and a beta of 0.51.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The firm had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22,438,500 billion. During the same quarter in the prior year, the firm earned $2.29 EPS. The business’s revenue for the quarter was up 5.3% compared to the same quarter last year.

Institutional Trading of Johnson & Johnson

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Tempus Wealth Planning LLC grew its stake in shares of Johnson & Johnson by 6.2% in the 4th quarter. Tempus Wealth Planning LLC now owns 9,352 shares of the company’s stock worth $1,353,000 after buying an additional 544 shares during the last quarter. Flavin Financial Services Inc. bought a new position in Johnson & Johnson in the 4th quarter valued at approximately $672,000. Calamos Wealth Management LLC lifted its position in Johnson & Johnson by 137.4% in the 4th quarter. Calamos Wealth Management LLC now owns 100,947 shares of the company’s stock valued at $14,599,000 after acquiring an additional 58,424 shares in the last quarter. Calamos Advisors LLC lifted its position in Johnson & Johnson by 0.5% in the 4th quarter. Calamos Advisors LLC now owns 564,754 shares of the company’s stock valued at $81,675,000 after acquiring an additional 2,888 shares in the last quarter. Finally, Columbus Macro LLC lifted its position in Johnson & Johnson by 59.0% in the 4th quarter. Columbus Macro LLC now owns 16,501 shares of the company’s stock valued at $2,386,000 after acquiring an additional 6,120 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insiders Place Their Bets

In other news, Director Mark A. Weinberger bought 1,000 shares of Johnson & Johnson stock in a transaction on Thursday, December 12th. The shares were purchased at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the acquisition, the director now owns 1,000 shares of the company’s stock, valued at approximately $147,220. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be issued a dividend of $1.24 per share. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.38%. Johnson & Johnson’s dividend payout ratio (DPR) is 74.59%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.